Citigroup’s Nexalin Technology NXL Stock Holding History

Citigroup’s Portfolio NXL Stock Details NXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-88	Closed	-$81	–	6337
2025 Q3	$81	Buy	+88	New	+$83	﹤0.01%	5819
2024 Q3	–	Sell	-1	Closed	-$2	–	5770
2024 Q2	$2	Buy	+1	New	+$1	﹤0.01%	5542

Other funds holding NXL

PEAK6 Chicago, Illinois $42.6B AUM 66.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citigroup's NXL Position: Q4 2025 in Review

Citigroup sold out of Nexalin Technology (NXL) in Q4 2025, closing a stake of 88 shares — an estimated $81 sold.

Citigroup first reported a position in NXL in Q2 2024 and held it in 2 quarters. The position peaked at $81 in Q3 2025. 19 funds tracked by Wall St. Rank hold NXL as of Q4 2025.

Citigroup reported no remaining Nexalin Technology position as of Q4 2025 after selling out during the quarter.
Citigroup sold 88 Nexalin Technology shares in Q4 2025, an estimated $81.
Citigroup first reported a position in Nexalin Technology in Q2 2024 and held it in 2 quarters.
Citigroup's Nexalin Technology position peaked at $81 in Q3 2025.
19 funds tracked by Wall St. Rank held Nexalin Technology as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.